Why the study?
Do ACE inhibitors, ARBs, or combination therapy reduce mortality and myocardial infarction in adults with stable ischemic heart disease and preserved ventricular function?
Population
Adults with stable ischemic heart disease and preserved ventricular function (41 studies included)
Comparison
Angiotensin-converting enzyme inhibitors… vs Placebo or active control
Design
Systematic_review
Follow-up
at least 6 months
Authors
Loading...
Supports ACE inhibitor addition in stable IHD with preserved function; confirms mortality and nonfatal MI reductions in Level 1 evidence.
Do ACE inhibitors, ARBs, or combination therapy reduce mortality and myocardial infarction in adults with stable ischemic heart disease and preserved ventricular function?
Adding an ACE inhibitor to standard medical therapy reduces mortality and myocardial infarctions in patients with stable ischemic heart disease and preserved ventricular function, whereas ARBs have less evidence of benefit and combination therapy increases harms without added benefit.
William L. Baker (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: